New drug cocktail aims to shrink Hard-to-Treat bladder tumors

NCT ID NCT04878029

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing whether combining two drugs—cabozantinib and enfortumab vedotin—can safely treat advanced bladder cancer that has spread. About 32 adults whose cancer worsened after standard treatments will receive the combo. The study aims to find the best dose and check for tumor shrinkage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
cabozantinib and enfortumab vedotin
What this could lead to
If this combination works, it could offer a new treatment option for people with advanced bladder cancer that has stopped responding to other therapies.
What could go wrong
This is a very early phase I trial with only 32 participants, so the main goal is safety and dosing—not yet proof of effectiveness. Side effects from combining two drugs could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFILTRATING BLADDER UROTHELIAL CARCINOMA WITH SQUAMOUS DIFFERENTIATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Emory University Hospital/Winship Cancer Institute

    RECRUITING

    Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.